Targeted regulation of FoxO1 in chondrocytes prevents age-related osteoarthritis via autophagy mechanism

Jiaji Yue | Aikebaier Aobulikasimu | Weichao Sun | Shuyu Liu | Wei Xie | Wei Sun

Department of Bone and Joint Surgery, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen, China

Correspondence
Wei Sun, Department of Bone and Joint Surgery, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, 3002 W Sungang Road, Shenzhen, Guangdong 518000, China.
Email: w_sun2020@outlook.com

Funding information
This work is supported by Guangdong Medical Research foundation, A2021321.

Abstract
Autophagy is designated as a biological recycling process to maintain cellular homeostasis by the sequestration of damaged proteins and organelles in plasma and cargo delivery to lysosomes for degradation and reclamation. This organelle recycling process promotes chondrocyte homeostasis and has been previously implicated in osteoarthritis (OA). Autophagy is widely involved in regulating chondrocyte degeneration markers such as MMPs, ADAMSTs and Col10 in chondrocytes. The critical autophagy-related (ATG) proteins have now been considered the protective factor against late-onset OA. The current research field proposes that the autophagic pathway is closely related to chondrocyte activity. However, the mechanism is complex yet needs precise elaboration. This review concluded that FoxO1, a forkhead O family protein, which is a decisive mediator of autophagy, facilitates the pathological process of osteoarthritis. Diverse mechanisms regulate the activity of FoxO1 and promote the initiation of autophagy, including the prominent AMPK and Sirt-2 cellular pathways. FoxO1 transactive is regulated by phosphorylation and acetylation processes, which modulates the downstream ATGs expression. Furthermore, FoxO1 induces autophagy by directly interacting with ATGs proteins, which control the formation of autophagosomes and lysosomes fusion. This review will discuss cutting-edge evidence that the FoxO–autophagy pathway plays an essential regulator in the pathogenesis of osteoarthritis.

KEYWORDS
autophagy, chondrocytes, FoxO1, osteoarthritis

Osteoarthritis is a widespread and incapacitating disease, with 250 million people are currently estimated affected. With the striking impacts of ageing and the rapidly expanding population in obesity worldwide, osteoarthritis exerts a substantial medical burden for the patients and healthcare systems. Osteoarthritis (OA) has gradually become one of the primary diseases that affect patients’ quality of life due to its high incidence and disability rate. Along with increasing quantities in sports injuries, the syndromic condition is becoming more socioeconomic burdensome.

The data reported by the Lancet show that the incidence of knee OA in people over 50 years old is about 14%–38% in Asia, 23% in Europe and about 19% in North America. Meanwhile, the consumption of medical resources accounts for 1%–2.5% of GDP in developed countries. At the same time, the indirect losses, including...
the decline in quality of life, the economic burden in medical rehabilitation and unemployment, are even more magnificent. The WHO data reveal that, by 2015, the years lived with disability (YLD) caused by OA accounted for approximately 3.9% of all diseases globally. By 2020, OA will become the fourth-largest cause of YLD loss.

Therefore, research in the pathogenesis and progression mechanism of OA disease and striving to explore feasible solutions and targets for treating or delaying the progression of the disease has significant clinical value and social significance.

1 | AGEING AND SENESCENCE-RELATED CHONDROCYTE APOPTOSIS IS THE CRITICAL DETERMINANT IN THE PATHOGENESIS OF OSTEOARTHRITIS

The aetiology of OA is complex and needs elaboration. Evidence shows a significant correlation between increased susceptibility to OA and ageing. In the early stage of OA progression, ageing promotes articular cartilage degeneration, elastic cartilage gradually degrades into fibrocartilage, and its cushioning and stabilizing effect on joints gradually declines. Cartilage fibrosis increases the compactness of collagen and impairs the microenvironment of chondrocytes. The hypertrophic pathogenesis changes such as morphology alteration and osteogenic differentiation are induced. Chronic injury-induced bleeding can cause aseptic inflammation of the synovium, chondrocytes and subchondral bone tissue in the articular cavity, thereby accelerating the destruction of the microenvironment and the degeneration of the extracellular cartilage matrix and ultimately leading to the initiation of chondrocytes apoptosis. Oxidative stress damage caused by ageing accumulates in chondrocytes. By interfering with cellular autophagy, the progress of apoptosis is stimulated, and ultimately causing chondrocytes and cartilage matrix to be replaced by osteoblasts and bone tissue. The pathogenesis alteration eventually induces membrane hyperplasia; inflammatory factors thrive in synovial fluid, cartilage calcification, subchondral bone sclerosis and various OA-specific pathological manifestations.

As an essential factor in stabilizing articular cartilage homeostasis, chondrocytes undergo a series of alterations in the OA progression. Disequilibrium of chondrocyte homeostasis by impairment causes the chondrocytes hypertrophy and further promotes osteogenic differentiation, eventually inducing cartilage degradation and apoptosis of chondrocytes. In the pathogenesis of degeneration, the expression of matrix metalloproteinases (MMP9 and MMP13) and various cartilage matrix proteases, such as ADAMTS5 and ADAMTS7, can enzymolysis the type II collagen (C10α1 and Acan) and proteoglycan (aggrecan, Acan) in the cartilage matrix. It produces decomposition, which further triggers the degeneration of the cartilage matrix and the transformation into a bone matrix. In the early stage of OA, autophagy-mediator LC3-II, beclin-1 and ATG5 in articular chondrocytes increased as the feedback reaction to homeostasis impairment. The expression of matrix proteases, such as MMP9, MMP13 and ADAMTS5, ADAMTS7 is inhibited, the metabolic decomposition of Acan, C10α1, and other multiple helix collagen protects cartilage is prevented. However, with the progress of OA disease, oxidative stress damage continues to accumulate, and the level of autophagy-mediated by LC3-II, beclin-1 and ATG5 in chondrocytes gradually decreases, and it promotes the hypertrophy marker of chondrocytes such as Runx2, C10α1 and MMP9. The increase in osteogenic differentiation markers leads to hypertrophy of chondrocytes and further differentiation into osteoblasts, which eventually triggers the activation of caspase3 and caspase9 and initiates the apoptosis program (Figure 1). In addition, as the content of elastic fibres in cartilage decreases, the increase in mechanical stress will also cause the reduction in the expression of ULK1, LC3-II and beclin-1 in chondrocytes, further accelerating the apoptosis of chondrocytes.

2 | AUTOPHAGY IS AN ESSENTIAL REGULATOR FOR CHONDROCYTE APOPTOSIS AND THE PATHOGENESIS OF OA

Studies have reported that autophagy plays a significant role in the biological development of bone and cartilage and maintaining physiological homeostasis. On the contrary, ageing exerts an imbalance in autophagy and causes deterioration in chondrocytes apoptosis. Developmental biology studies in mice have revealed that fibroblast growth factor 18 (FGF-18) activates JNK1 through the fibroblast growth factor receptor 4 (FGFR-4) signalling pathway, which activates the autophagy-related protein 7 (ATG 7) and the downstream autophagy-mediated type II collagen secretion in chondrocytes. In the ageing mice model, chondrocytes showed a significant decrease in the number of autophagosomes before the pathological alteration of OA. Meanwhile, a reduction in the ATG5 and LC3 and an increase in the apoptosis marker poly ADP-ribose polymerase (PARP) reveal the impairment of chondrocyte homeostasis. With the gradual aggravation of ageing, the level of LC3-II in chondrocytes decreases progressively, and the expression of MMP13 increases progressively, all of which continue to indicate a correlation of autophagy inhibition and OA progression.

The ATG5 knockout mouse model indicated that the gene and protein levels of C10α1 and Acan decreased significantly, while the expression of matrix protease MMP13 and ADAMTS5 increased. This study also reflects that autophagy in chondrocytes functions as the protector of cartilage degradation. The sirolimus or rapamycin inhibits the mammalian target of rapamycin (mTOR) signalling pathway and significantly increases the expression of C10α1, Acan and Sox9 in ATDC5 chondrocytes. The catabolism markers C10α1, MMP9, MMP13 and ADAMTS5 and the apoptosis markers caspase3, caspase9, beclin-1 and beclin-2 significantly reduced. The above-mentioned evidence further confirms that autophagy is important in maintaining chondrocytes and cartilage matrix homeostasis and inhibiting chondrocyte apoptosis. The histological study of clinical cases also found similar results, and mTOR expression...
increased in joint samples of patients with OA. The specific ligand rapamycin can bind to the intracellular receptor FKBP-12 to form a complex and act directly on mTOR. The FRB domain (FKBP-12-rapamycin binding site) can effectively inhibit its protein activity and increase the level of autophagy. Therefore, regulating the mTOR signalling pathway of autophagy upstream can effectively reduce the destruction of the cartilage matrix. 14,15 Similarly, the mTOR knockout mouse model reveals that autophagy was significantly activated in chondrocytes, effectively reducing chondrocyte apoptosis and maintaining the homeostasis of the articular cartilage microenvironment. Articular cartilage degeneration decelerated in the surgical-induced OA mouse model.16 On the contrary, chondrocyte-targeted ATG5 and ATG7 knocked out mouse model reveals the accumulation in caspase-mediated apoptosis and acceleration of OA disease progression.17

3  | FoxO1 IS THE DOMINANT TRANSCRIPTION FACTOR REGULATING THE OA PROGRESSION

The FoxO (Forkhead-box class O) transcription factor family for mammals mainly includes FoxO1, FoxO3, FoxO4 and FoxO6, which perform distinct and overlapping functions. The domain of its specific DNA binding site comprises three alpha-helices and two characteristic outer loops, as the shape of a fork. FoxO is mainly involved in the physiological regulation of biological development and ageing, which is closely related to the lifespan of vertebrates. In addition, FoxO transcription factors are also involved in critical roles such as preventing oxidative stress damage and maintaining homeostasis of the intracellular environment.19 Even though FoxO1, FoxO3 and FoxO4 are expressed ubiquitously in multiple organs, the gene regulation of each FoxO conforms to a tissue-specific pattern, while FoxO6 expression largely correlates to neurological function.20,21 FoxO1 is primarily expressed in bone and cartilage and functions as an essential factor in regulating bone tissue development and maintaining chondrocyte homeostasis.22 FoxO1 interacts with Runx223,24 and Wnt/β-catenin cellular pathway in osseous tissue to regulate osteoblast differentiation and further modulates energy metabolism to influence bone development.22,25 The longevity of homosapien is associated with the polymorphisms of FoxO3.26 FoxOs are the downstream target of phosphoinositide-3 kinase (PI3K)/Akt signalling, which modulate cell proliferation, growth, apoptosis, and the expression of antioxidant and autophagy proteins.27 FoxO controls the cellular homeostasis and the subsistence of stem cells in development to maintain the biological function of the tissue.27 FoxOs also regulate the self-renewal of stem cell populations28 and are involved in the regulation of cell differentiation.29 Oxidative stress induces the FoxOs expression and transcription. The downstream antioxidant enzymes, including catalase and manganese superoxide dismutase, are activated to prevent impairment of cellular homeostasis.30 Besides, autophagy and ubiquitin-proteasome system are the two primary intracellular clearance mechanisms regulated by the transcriptional function of FoxOs. Recycling and eliminating damaged organelle and dysfunctioned protein are significant for cellular homeostasis. FoxO-mediated autophagy has been implicated as the essential regulator for chondrocytes homeostasis preventing the
FoxO1 expression decreases in the cartilage of elderly OA patients, especially in the superficial layer of the cartilage in the weight-bearing area. Similarly, in the fibrosis area and osteophytes hyperplasia area, FoxO1 presents a significantly lower expression, which reveals the phenomenal correlation between OA progression and FoxO1 expression. Animal experiments reveal that FoxO1 expression gradually decreased with increased mouse age and the chondrocytes with lower FoxO1 expression aggregated in the cartilage not covered by the meniscus. The accumulation of microdamage induced by biomechanical stress on the cartilage regulates the FoxO1 expression and OA progression. Apart from cartilage degradation, the meniscus damage accounted for the primary factor for knee OA. FoxO1 and FoxO3 are more abundant than FoxO4 in human menisci, and FoxO1 and FoxO3 show similar expression in the whole meniscus regions. In mature mice, a higher expression of FoxO1 and FoxO3 shows in the meniscus's superficial zone and posterior region. In degenerated meniscus, FoxOs, especially FoxO1 and FoxO3, are depressed, revealing their protective functions during ageing-induced OA progression.

Ageing is the leading risk factor for meniscus degeneration. The histological autopsy analysis of human knee joints reveals that meniscus from donors with normal articular cartilage presented minimal reduced FoxO1 or FoxO3 expression. On the contrary, mice showed ageing-related meniscus damage and lowered FoxO1 and FoxO3 expression at 12-month age, where FoxO1 and FoxO3 expressions decreased in the posterior vascular zone. Similar to the ageing-induced OA model, reduced FoxO expression correlates to meniscus degradation in DMM and treadmill-induced OA. Col2a1 and Acan aggregated in the superficial and avascular area of the meniscus, prominently in the inner third. Besides, Col2a1 expression is relatively extensive in fibrochondrocytes of anterior and posterior meniscus horns. The Acan-CreERT2 FoxO TKO mice spontaneously developed more severe histopathological changes than the meniscus in control mice by 9 months, and treadmill running-induced meniscus damage was also more stringent. The Acan-CreERT2-FoxO TKO mice show that FoxO is indispensable for the subsistence of meniscus integrity during adulthood, where cultured human meniscus cells with FoxO1 overexpression reveal similar results. FoxO1 regulates chondrocytes viability and cartilage homeostasis, including autophagy, ECM, transcription factors, antioxidant defence, ECM degradation and inflammation. In the meniscus from arthrotrauma, compromised autophagy and suppression of FoxO reveal the protective mechanism against chondrocyte deterioration. The critical articular lubricant, PRG4, is also regulated by FoxO1 to prevent damage from mechanical stress. PRG4 is the secretion from the synovium chondrocytes from the superficial zone of articular cartilage and meniscus. In FoxO KO mice, PRG4 presents the lower expression, causing the cartilage to be more susceptible to mechanical stress damage. The chondrocytes in FoxO-deficient animal models are characterized with hypertrophic morphology, associated with increased abnormal expression of hypertrophy-related genes. In this regard, FoxO suppression in the chondrocytes might contribute to cartilage degradation and calcification, cellular autophagy impairment and PRG4 decrease, leading to OA's pathogenesis.

4 | **FoxO1-MEDITATED CELLULAR AUTOPHAGY MAINTAINS THE HOMEOSTASIS OF CHONDROCYTES**

FoxO1 is the dominant downstream target in the PI3K-Akt kinase pathway and AMPK-JNK kinase signalling pathway, generally involved in critical physiological functions such as apoptosis, energy metabolism, cell cycle and differentiation. FoxO binds to the gene promoter and up-regulates the expression of ATGs genes to activate the downstream autophagy initiation. After the transcription and translation of FoxO from the nucleus into the cytosolic compartment, FoxO undergoes various post-translational modifications (PTM) such as AMPK phosphorylation, Sirt1/2 acetylation or PRMT6 methylation, which promotes FoxO translocation to the nucleus and activates autophagy initiation. Among all, Sirt1/2-induced acetylation is indispensable in regulating FoxO1 activity. Sirt1/2 acetylates FoxO1 transcription factor at Lys262, Lys265 and Lys274 in human FoxO1, and AMPK pathway phosphorylates at Thr24, Ser256 and Ser319 in mouse FoxO1, or Thr32, Ser253 and Ser315 in human FoxO1. PTMs can effectively activate multiple phases in the process of autophagy, including phagophore induction (e.g. Ulk1 and Ulk2), nucleation (e.g. Becn1 and Atg14), elongation (e.g. Map1lc3b, Gabarapl and Atg4) and fusion of autophagosomes and lysosomes (e.g. Tfeb, Rab7) (Figure 2). Additionally, FoxO transcription factors activate mTORC1 by inducing sestrin3 (Sesn3), the promoter of AMPK and deactivator of mTORC1, eliminating the inhibition of autophagy initiation. In general, the mechanism of autophagy regulation is complicated and involved in various signalling pathways.
Therefore, the elaboration of the FoxO1 pathway has a fundamental clinical significance for OA pathogenesis.

Studies have revealed multiple cellular pathways regulating the initiation of autophagy and the process of autophagosome formation. AMP-activated protein kinase (AMPK) stimulates the FoxO transcription and induces the ATGs activation to function as the dominant regulator of the autophagy activation pathway. Besides, the beclin-1 complex and serine/threonine-protein kinase 1 (Unc-51 like autophagy activating kinase, ULK1) coordinate the activation of autophagy as well. The mTOR signalling pathway is mainly involved in inhibiting autophagy. AMPK alteration is sensitive to various cell oxidative stress injuries. The activation of kinase in AMPK promotes the downstream target phosphorylation, including ULK1 and mTORC1, acting as the initiator of autophagy. The ULK1 complex, which consists of ULK1, ATG13, ATG101 and FIP200, positively regulates autophagy resulting in the initiation of autophagosomes formation. AMPK-induced phosphorylation of ULK1 itself promotes the early-stage autophagosome formation. The autophagosome initiation elevates the aggregation of other ATGs proteins to accelerate the elongation and maturation of the autophagosomes. ATG7 is the dominant protein regulating the autophagosome initiation, which functions as the ubiquitin-like modiﬁer-activating enzyme. ATG5 is ubiquitylated by ATG7 and combined with ATG12 to form a functional complex. This protein complex acts as an E3-ubiquitin-like ligase, promoting the lipidation of the cytoplasmic form of microtubule-associated proteins 1A/1B light chain 3A (LC3), known as LC3-I, and converting it to the membrane-bound phosphatidylethanolamine-conjugated format, known as LC3-II. The structural alteration of LC3-I to LC3-II is the fundamental of autophagosomes maturation. The conversion of LC3-I to LC3-II is an essential process in the maturation of autophagosomes, which facilitates the amalgamation of lysosomes for substance degradation and recycling. In the autophagy formation process, the beclin-1 complex is regulated by phosphatidylinositol 3-kinase (PI3K) and binds to the inner membrane structure in the cell (endoplasmic reticulum, mitochondria or nuclear membrane), promoting the ULK1 complex to form the outer membrane structure of the autophagosomes. The colonization of ATG14L facilitates the transport and maturation of autophagosomes. On the contrary, ULK1 can also negatively regulate AMPK and deactivate autophagy. The mTOR can phosphorylate ATG13 to inhibit the outer membrane formation for the ULK1 complex.

The impacts of FoxO1 phosphorylation on autophagy are significantly different in various pathways and cells. Phosphorylation induced by AKT, ERK, MEK and AMPK is the essential PTMs of FoxO1 that trigger the alteration of subcellular localization. Phosphorylated-FoxO1(p-FoxO1) is restricted in the cytoplasm and interacts with ubiquitin E3 ligases, evoking the degeneration of FoxO1. Furthermore, p-FoxO1 binding to 14-3-3 protein extends the physical distance of FoxO1 and downstream target, preventing the binding and activation of targeted DNA from transcription. That ERK cellular pathway is one of the critical signals of FoxO1 phosphorylation. The inhibition of ERK and MEK attenuate phosphorylation resulting in the activation of FoxO1 in rat hepatocytes. Phosphorylation of FoxO1 is invalid in binding to ATG7 for autophagy initiation in mouse ovarian granulosa cells. The FSH or melatonin induces both Akt-mediated phosphorylation and Sirt1-mediated deacetylation of FoxO1. However, neither FoxO1-ATG7 interaction nor autophagy upregulation was verified. Interestingly, a recent study revealed a specific result that phosphorylated cytosolic FoxO1 associates with Atg7 to induce autophagy in iNKS, which is essential for NK cell development. Modified FoxO1 promotes the interaction with ATG7 and stabilizes FoxO1 in iNKS cytoplasm, leading to the autophagy initiation. A comparable study has suggested that Akt-induced FoxO1 phosphorylation excludes FoxO1 from the nucleus to cytoplasm, resulting in the enhancement of FoxO1-Atg7 interaction and promoting autophagy activation in the cytoplasm.

The AMPK-FoxO-autophagy pathway contributes to cell viability with the essential adaptation mechanism, maintaining cellular homeostasis from environmental stresses, primarily protecting chondrocytes from exercise-induced hypoxia and microdamage. AMPK induces FoxO3 phosphorylation at Ser413 or Ser588 and stabilizes the activation in nutrient deﬁcient or hypoxia situations. The nucleus accumulation of p-FoxO3 significantly increases autophagy gene transcription and promotes autophagy via transcriptional or epigenetic mechanisms. Likewise, FoxO3 is phosphorylated by c-Jun N-terminal kinase (JNK) at Ser294, inducing nuclear translocation under oxidative stress. JNK-FoxO3-autophagy pathway plays a critical role in bone remodelling. By elevating the mitochondrial metabolism, the JNK-FoxO3-autophagy pathway promotes the differentiation of mesenchymal stem cells into osteoblasts, which is vital for bone homeostasis. FoxO1 is proved to be indirectly phosphorylated by JNK at Ser246 through cyclin-dependent protein kinase (CDK) in neurons and activates AMPK via SESN to promote autophagy activation.

Apart from binding to the promoters to upregulate the expression of autophagy-related genes, FoxOs independently activate autophagy without transactivation functions. FoxOs translocate from the nucleus to the cytosolic compartment and combine directly to the E1-like enzyme, ATG7, to elevate autophagy activity. The acetylation (e.g. Lys262, Lys265 and Lys274 in Homo sapiens FoxO1) and Akt-induced phosphorylation (e.g. Thr24, Ser256 and Ser319 for Mus musculus Foxo1, and Thr32, Ser253 and Ser315 for H. sapiens FoxO1) are critical for FoxO1 translocation into the cytoplasm and the Atg7 interaction for autophagy induction. Stress conditions promoted the dissociation of deacetylases Sirt1 or Sirt2 from their substrate FoxO1, which signiﬁcantly upregulated the acetylation of FoxO1. SIRT1 functions as the autophagy initiator primarily in the nucleus, while SIRT2 acts as the dominant deacetylase of FoxO1 primarily in the cytosol. Three acetylation sites of FoxO1 (Lys 262, Lys 265 and Lys 274) have been identiﬁed as the functional target of SIRT2. Deacetylated FoxO1 can promote the activation of autophagy. In 3T3-L1 preadipocytes, a recent study has proved the indirect interaction of SIRT2 and FoxO1. In response to stimuli, the release of SIRT2 from FoxO1 induces acetylation and promotes its...
transactivation,75,76 and cytosolic FoxO1 is primarily accountable for the initiation of autophagy. In human colon tumours, the acetylated FoxO1 and ATG7 complex functions as the dominant initiator for autophagosome formation (Figure 3). ATG7 functions as the E1-like protein to activate ATG12 by forming a thioester bond between Cys 507 of Atg7 and Gly 186 of Atg12. The activation of ATG12 by ATG7 is indispensable for inducing ATG12-ATG5 conjugates and membrane-bound LC3-II in mammalian cells.77 The acetylation of FoxO1 is essential for autophagy initiation. However, enhancing ATG7 activity after the interaction with acetylated FoxO1 still needs detailed elaboration. The physiological mechanism of the FoxO1 signalling pathway in chondrocytes requires specific exposition. This review discussed, at least in part, how the FoxO1 correlated with autophagy initiation and the protective ability in cartilage and bone homeostasis.

CONFLICT OF INTERESTS
All authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTION
Jiaji Yue: Funding acquisition (lead); Writing – original draft (lead). Weichao Sun: Visualization (equal). Aikebaier Aobilikasimu: Writing – original draft (supporting). Shuyu Liu: Visualization (equal). Wei Xie: Writing – review & editing (supporting). Wei Sun: Writing – review & editing (equal).

ETHICAL APPROVAL
The ethical approval was exempted by the institutional review board of Shenzhen Second People’s Hospital.

ORCID
Jiaji Yue https://orcid.org/0000-0001-8113-4577

REFERENCES
1. Woolf AD, Pfieger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646–656.
2. Prieto-Alhambra D, Judge A, Javid MK, Cooper C, Diez-Perez A, Arden NK. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014;73(9):1659–1664.
3. Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014;10(7):437–441.
4. Hunter DJ, Bierer-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–1759.
5. Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602.
6. Shkhyan R, Van Handel B, Bogdanov J, et al. Drug-induced modulation of gp130 signalling prevents articular cartilage degeneration and promotes repair. Ann Rheum Dis. 2018;77(5):760–769.
7. Kim JH, Jeon J, Shin M, et al. Regulation of the catabolic cascade in osteoarthritis by the zinc-ZIP8-MTF1 axis. Cell. 2014;156(4):730–743.
8. Yang H, Wen Y, Zhang M, et al. MTORC1 coordinates the autophagy and apoptosis signaling in articular chondrocytes in osteoarthritic temporomandibular joint. Autophagy. 2020;16(2):271–288.
9. Zheng W, Li X, Liu D, et al. Mechanical loading mitigates osteoarthritis symptoms by regulating endoplasmic reticulum stress and autophagy. FASEB J. 2019;33(3):4077–4088.
10. Cinque L, Forrester A, Bartolomeo R, et al. FGF signalling regulates bone growth through autophagy. Nature. 2015;528(7581):272–275.
11. Rockel JS, Kapoor M. Autophagy: controlling cell fate in rheumatic diseases. Nat Rev Rheumatol. 2017;13(3):193.
12. Wang C, Xu W, Zhang Y, Zhang F, Huang K. PARP1 promote autophagy and apoptosis in articular chondrocytes via regulating FoxO3a transcription. Cell Death Dis. 2018;9(11):1047.
13. Bouderlique T, Vuppalapati KK, Newton PT, Li L, Barenbus C, Chagin A. Targeted deletion of Atg5 in chondrocytes promotes age-related osteoarthritis. Ann Rheum Dis. 2016;75(3):627–631.
14. Ansari MY, Ahmad N, Haqqi TM. Butein activates autophagy through AMPK/TSC2/ULK1/mTOR pathway to inhibit IL-6
expression in IL-1beta stimulated human chondrocytes. Cell Physiol Biochem. 2018;49(3):932-946.

15. Yang H, Jiang X, Li B, et al. Mechanisms of mTORC1 activation by RHEB and inhibition by PRA540. Nature. 2017;552(7685):368-373.

16. Alvarez-Garcia O, Matsuzaki T, Olmer M, Plate L, Kelly JW, Lotz MK. Regulated in Development and DNA Damage Response 1 deficiency impairs autophagy and mitochondrial biogenesis in articular cartilage and increases the severity of experimental osteoarthritis. Arthritis Rheumatol. 2017;69(7):1418-1428.

17. Bao J, Chen Z, Xu L, Wu L, Xiong Y. Rapamycin protects chondrocytes against IL-18-induced apoptosis and ameliorates rat osteoarthritis. Aging (Albany NY). 2020;12(6):5152-5167.

18. Cheng Z. The FoxO-autophagy axis in health and disease. Trends Endocrinol Metab. 2019;30(9):658-671.

19. Alvarez-Garcia O, Matsuzaki T, Olmer M, et al. FOXO are required for intervertebral disk homeostasis during aging and their deficiency promotes disk degeneration. Aging Cell. 2018;17(5):e12800.

20. Eijkelenboom A, Mokry M, deWit E, et al. Genome-wide analysis implicates the FoxO1 transcription factor in diabetic mice. Proc Natl Acad Sci USA. 2020;117(6):3135-3143.

21. Eijkelenboom A, Mokry M, deWit E, et al. Genome-wide analysis implicates the FoxO1 transcription factor in diabetic mice. Proc Natl Acad Sci USA. 2020;117(6):3135-3143.

22. Siqueira MF, Flowers S, Bhattacharya R, et al. FOXO1 modulates osteoblast differentiation. Bone. 2011;48(5):1043-1051.

23. Iyer S, Han L, Bartell SM, et al. Sirtuin1 (Sirt1) promotes cortical bone formation by preventing beta-catenin sequestration by FoxO transcription factors in osteoblast progenitors. J Biol Chem. 2014;289(35):24069-24078.

24. Xiong Y, Zhang Y, Xin N, et al. 1alpha,25-Dihydroxyvitamin D3 promotes bone formation by promoting nuclear exclusion of the FoxO1 transcription factor in diabetic mice. J Biol Chem. 2017;292(49):20270-20280.

25. Willcox BJ, Donlon TA, He Q, et al. FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci USA. 2008;105(37):13987-13992.

26. Webb AE, Brunet A. FOXO transcription factors: key regulators of cellular quality control. Trends Biochem Sci. 2014;39(4):159-169.

27. Zhang X, Yalcin S, Lee DF, et al. FOXO1 is an essential regulator of pluripotency in human embryonic stem cells. Nat Cell Biol. 2011;13(9):1092-1099.

28. Talchai SC, Accili D. Legacy effect of Foxo1 in pancreatic endocrine progenitors on adult beta-cell mass and function. Diabetes. 2015;64(8):2868-2879.

29. Rached MT, Kode A, Xu L, et al. FoxO1 is a positive regulator of oxidative damage in mouse ovarian granulosa cells by repressing autophagy. Autophagy. 2017;13(8):1364-1385.

30. Yang Y, Blee AM, Wang D, et al. Loss of FOXO1 cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion. Cancer Res. 2017;77(23):6524-6537.

31. Wang S, Xia P, Huang G, et al. FoxO1-mediated autophagy is required for NK cell development and innate immunity. Nat Commun. 2016;7:11023.

32. Sanchez AMJ, Candau R, Bernardi H. AMP-activated protein kinase stabilizes FOXO3 in primary myotubes. Biochim Biophys Res Commun. 2018;499(3):493-498.

33. Shen M, Jiang Y, Guan Z, et al. Protective mechanism of FOXO3 against oxidative damage in mouse ovarian granulosa cells by repressing autophagy. Autophagy. 2017;13(8):1364-1385.

34. Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate oxidative damage in mouse ovarian granulosa cells by repressing autophagy. Autophagy. 2017;13(8):1364-1385.

35. Pauli C, Grogan SP, Patidl S, et al. TRPML1 links lysosomal homeostasis and osteoarthritis. Aging Cell. 2018;17(5):e12800.

36. Henry SP, Jang CW, Deng JM, Zhang Z, Behringer RR, de Crombrugge B. Generation of aggrecan-CreERT2 knockin mice for inducible Cre activity in adult cartilage. Genesis. 2009;47(12):805-814.

37. Kambic HE, McDevitt CA. Spatial organization of types I and II collagen in the canine meniscus. J Orthop Res. 2005;23(1):142-149.

38. McKeever JK, Carames B, Olmer M, et al. Compromised autophagy precedes meniscus degeneration and cartilage damage in mice. Osteoarthritis Cartilage. 2017;25(11):1880-1889.

39. Jay GD, Waller KA. The biology of lubricin: near frictionless joint motion. Matrix Biol. 2014;39-47:17-24.

40. Sun Y, Mauerhan DR. Meniscal calcification, pathogenesis and implications. Curr Opin Rheumatol. 2012;24(2):152-157.

41. Shin HJ, Kim H, Oh S, et al. AMPK-SPK2-CARM1 signalling cascade in transcriptional regulation of autophagy. Nature. 2016;534(7608):553-557.

42. Miki Y, Tanji K, Mori F, et al. Autophagy mediators (FOXO1, ULK1 and PtdIns3K complex) are critical regulators of diabetes-related muscle atrophy. Diabetes. 2019;68(3):556-570.

43. Li L, Zviti R, Ha C, Wang ZY, Hill JA, Lin F. Forkhead box O3 (FoxO3) regulates kidney tubular autophagy following urinary tract obstruction. J Biol Chem. 2017;292(33):13774-13783.

44. Sanchez AMJ, Candau R, Bernardi H. AMP-activated protein kinase stabilizes FOXO3 in primary myotubes. Biochim Biophys Res Commun. 2018;499(3):493-498.

45. Miki Y, Tanji K, Mori F, et al. Autophagy mediators (FOXO1, SESN3 and TSC2) in Lewy body disease and aging. Neurosci Lett. 2018;684:35-41.

46. Puustinen P, Keldsbo A, Corcelle-Termue E, et al. DNA-dependent protein kinase regulates lysosomal AMP-dependent protein kinase activation and autophagy. Autophagy. 2020;16(10):1871-1888.

47. Scotto RA, Montefusco S, Soldati C, et al. TRPML1 links lysosomal calcium to autophagosome biogenesis through the activation of the CaMKKbeta/VPS34 pathway. Nat Commun. 2019;10(1):5630.

48. Kim J, Kuno M, Viellet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation ofULK1. Nat Cell Biol. 2011;13(2):132-141.

49. Kim BW, Jin Y, Kim J, et al. The C-terminal region of ATG16L1 bridges ULK1 and PtdIns3K complex in autophagy initiation. Autophagy. 2018;14(12):2104-2116.

50. Mizushima N, Noda T, Yoshimori T, et al. A protein conjugation system essential for autophagy. Nature. 1998;395(6700):395-398.

51. Fujita N, Itoh T, Omori H, Fukuda M, Noda T, Yoshimori T. The Atg16L complex specifies the site of LC3 lipidation for membrane biogenesis in autophagy. Mol Biol Cell. 2008;19(5):2092-2100.

52. Kuo CJ, Hansen M, Troemel E. Autophagy and innate immunity: Insights from invertebrate model organisms. Autophagy. 2018;14(2):233-242.
59. Xing YQ, Li A, Yang Y, Li XX, Zhang LN, Guo HC. The regulation of FOXO1 and its role in disease progression. Life Sci. 2018;193:124-131.
60. Mezza T, Shirakawa J, Martinez R, Hu J, Giaccari A, Kulkarni RN. Nuclear export of FoxO1 is associated with ERK signaling in beta-cells lacking insulin receptors. J Biol Chem. 2016;291(41):21485-21495.
61. Diaz D, Pai R, Cain G, et al. MEK and ERK kinase inhibitors increase circulating ceruloplasmin and cause green serum in rats. Toxicol Pathol. 2017;45(2):353-361.
62. Ju Y, Xu T, Zhang H, Yu A. FOXO1-dependent DNA damage repair is regulated by JNK in lung cancer cells. Int J Oncol. 2014;44(4):1284-1292.
63. Schall D, Schmitt F, Reis B, Brandt S, Beer-Hammer S. Sly1 regulates T-cell proliferation during Listeria monocytogenes infection in a Foxo1-dependent manner. Eur J Immunol. 2015;45(11):3087-3097.
64. Wimmer RJ, Russell SJ, Schneider MF. Green tea component EGCG, insulin and IGF-1 promote nuclear efflux of atrophy-associated transcription factor Foxo1 in skeletal muscle fibers. J Nutr Biochem. 2015;26(12):1559-1567.
65. Zhou J, Liao W, Yang J, et al. FOXO3 induces FOXO1-dependent autophagy by activating the AKT1 signaling pathway. Autophagy. 2012;8(12):1712-1723.
66. Yang M, Pi H, Li M, et al. From the cover: autophagy induction contributes to cadmium toxicity in mesenchymal stem cells via AMPK/FOXO3a/BECN1 signaling. Toxicol Sci. 2016;154(1):101-114.
67. Chi Y, Shi C, Zhao Y, Guo C. Forkhead box O (FOXO) 3 modulates hypoxia-induced autophagy through AMPK/FOXO3a/BECN1 signaling. Toxicol Sci. 2016;154(1):101-114.
68. Gomez-Puerto MC, Verhagen LP, Braat AK, Lam EW, Coffer PJ, Lorenowicz MJ. Activation of autophagy by FOXO3 regulates redox homeostasis during osteogenic differentiation. Autophagy. 2016;12(10):1804-1816.
69. Xu P, Das M, Reilly J, Davis RJ. JNK regulates FoxO-dependent autophagy in neurons. Genes Dev. 2011;25(4):310-322.
70. Wang B, Ding W, Zhang M, et al. Role of FOXO1 in aldosterone-induced autophagy: a compensatory protective mechanism related to podocyte injury. Oncotarget. 2016;7(29):45331-45351.
71. Zhao Y, Yang J, Liao W, et al. Cytoplasmic FoxO1 is essential for the induction of autophagy and tumour suppressor activity. Nat Cell Biol. 2010;12(7):665-675.
72. Lee IH, Cao L, Mostoslavsky R, et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA. 2008;105(9):3374-3379.
73. Dryden SC, Nahhas FA, Nowak JE, Goustin AS, Tainsky MA. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol. 2003;23(9):3173-3185.
74. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell. 2003;11(2):437-444.
75. Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab. 2007;6(2):105-114.
76. Wang F, Tong Q. SIRT2 suppresses adipocyte differentiation by deacetylating FOXO1 and enhancing FOXO1’s repressive interaction with PPARgamma. Mol Biol Cell. 2009;20(3):801-808.
77. Sou YS, Tanidal, Komatsu M, Ueno T,Kominami E. Phosphatidylserine in addition to phosphatidylethanolamine is an in vitro target of the mammalian Atg8 modifiers, LC3, GABARAP, and GATE-16. J Biol Chem. 2006;281(6):3017-3024.

How to cite this article: Yue J, Aobulikasimu A, Sun W, Liu S, Xie W, Sun W. Targeted regulation of FoxO1 in chondrocytes prevents age-related osteoarthritis via autophagy mechanism. J Cell Mol Med. 2022;26:3075–3082. doi:10.1111/jcmm.17319